ステージ I ~ II の黒色腫患者のマイクロバイオームに対する手術前の抗生物質 (セファゾリン) の影響
皮膚悪性腫瘍患者のマイクロバイオームに対する周術期の抗生物質予防投与の影響の評価
This phase I trial investigates the impact of cefazolin before surgery on the microbiome in patients with stage I-II melanoma. Antibiotics, such as cefazolin, given at the time of surgery may cause a significant change in the microbes (like bacteria and viruses) found in the stomach and intestines. This trial may help researchers learn if any changes in microbes affect the body's ability to respond to surgery and cancer.
調査の概要
状態
条件
- 臨床病期 I 皮膚黒色腫 AJCC v8
- 臨床病期 IA 皮膚黒色腫 AJCC v8
- 臨床病期 IB 皮膚黒色腫 AJCC v8
- 臨床病期 II 皮膚黒色腫 AJCC v8
- 臨床病期 IIA 皮膚黒色腫 AJCC v8
- 臨床病期 IIB 皮膚黒色腫 AJCC v8
- 臨床病期 IIC 皮膚黒色腫 AJCC v8
- 病理学的ステージ I 皮膚黒色腫 AJCC v8
- 病期 IA 皮膚黒色腫 AJCC v8
- 病理学的 IB 期 皮膚黒色腫 AJCC v8
- 病理学的ステージ II 皮膚黒色腫 AJCC v8
- 病理学的ステージ IIA 皮膚黒色腫 AJCC v8
- 病理学的ステージ IIB 皮膚黒色腫 AJCC v8
- 病期 IIC 皮膚黒色腫 AJCC v8
介入・治療
詳細な説明
PRIMARY OBJECTIVE:
I. To investigate whether the use of pre-operative prophylactic antibiotics administered during surgical resection substantially alters the patient's gut microbiome.
SECONDARY OBJECTIVES:
I. To characterize the dynamics of the immune response to surgical intervention in the absence and presence of pre-operative prophylactic antibiotics, focusing on the immune profile of the peripheral blood leukocytes as well as the balance of circulating pro- and anti-inflammatory cytokines and metabolomic profiles.
II. To assess surgical site infection (SSI) in the absence and presence of pre-operative prophylactic antibiotics at time of surgical resection.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive cefazolin intravenously (IV) and then undergo standard of care surgical resection within 1 hour.
ARM B: Patients undergo standard of care surgical resection.
After completion of study treatment, patients are followed up at 3 days, 2 weeks, and 3 months.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- M D Anderson Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adult subjects with early stage melanoma (stage I-II)
- Patients must be undergoing wide local excision +/- sentinel lymph node biopsy
- Patients must be capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
Exclusion Criteria:
- Use of antibiotics within the three months prior to surgery
- Allergy, sensitivity or anaphylaxis to beta-lactam or cephalosporin antibiotics
- Presence of an infection at the time of surgery
- Increased risk of infection due to a co-existing medical condition as determined by the surgical team or principal investigator (PI)
- Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration
- American Society of Anesthesiologists (ASA) grade > IV
- Refusal to participate in the study
- Patients who are pregnant will not be included in this study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Arm A (cefazolin, surgical resection)
Patients receive cefazolin IV and then undergo standard of care surgical resection within 1 hour. |
Given IV Undergo standard of care surgical resection
他の名前:
|
|
実験的:Arm B (surgical resection)
Patients undergo standard of care surgical resection. |
Undergo standard of care surgical resection
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in microbiome alpha diversity
時間枠:Baseline up to 2 weeks post-surgery
|
The diversity, structure, and composition of the fecal microbiome will be determined by 16S(v4) rRNA gene sequencing. 16S profiles will be used to compute alpha diversity, beta diversity, and the relative abundance of fecal bacteria. The composition of fecal bacteria in adult humans is mainly dominated by members of the Firmicutes and Proteobacteria phyla while members of Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomicrobia are observed in lower abundance. To calculate richness (alpha-diversity), we will count each operational taxonomic unit (OTU) or amplicon sequence variant (ASV) identified. Richness count is expected to range between 10-500 per sample. |
Baseline up to 2 weeks post-surgery
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
微生物の相対存在量の変化
時間枠:ベースライン、手術後 2 週間、および手術後 3 か月
|
ベースライン、手術後 2 週間、および手術後 3 か月
|
|
|
創傷(手術部位)感染率
時間枠:術後3ヶ月まで
|
術後3ヶ月まで
|
|
|
Change in microbiome diversity
時間枠:Baseline up to 3 months post-surgery
|
The diversity, structure, and composition of the fecal microbiome will be determined by 16S(v4) rRNA gene sequencing. 16S profiles will be used to compute alpha diversity, beta diversity, and the relative abundance of fecal bacteria. The composition of fecal bacteria in adult humans is mainly dominated by members of the Firmicutes and Proteobacteria phyla while members of Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomicrobia are observed in lower abundance. To calculate richness (alpha-diversity), we will count each operational taxonomic unit (OTU) or amplicon sequence variant (ASV) identified. Richness count is expected to range between 10-500 per sample. |
Baseline up to 3 months post-surgery
|
|
Profiling of systemic immune function by analysis of composition of circulating immune cell populations and cytokines
時間枠:Up to 3 months post-surgery
|
By analysis of composition of circulating immune cell populations and cytokines. |
Up to 3 months post-surgery
|
協力者と研究者
捜査官
- 主任研究者:Emily Z Keung、M.D. Anderson Cancer Center
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。